Friday, 16 October 2026European Markets

BARBARA BUI Stock Over 11% Down So Far On Monday

Loading stream...

shares of paris-based apparel manufacturer barbara bui (cac 40: bui.pa) experienced a significant fall recently. after five consecutive sessions of decline, shares dropped by 11% to eur8.90 at 14:52 est monday afternoon. this occurred even as france's cac 40 index nudged forward slightly by 0.14% to eur7,350.65.

performance figures

as recently as the last close, barbara bui was trading at eur10.00. this marks a 4.76% fall from its 52-week high of eur10.50. despite this, its current value is still notably above its 52-week low of eur6.30.

earnings and ratio

barbara bui's trailing twelve-month earnings per share (eps) came in at eur1.61, and the firm's price-earnings ratio is currently at 5.53. this means that investors pay eur5.53 for every euro of annual earnings reported by the company.

profitability and returns

undoubtedly, barbara bui has exhibited strong profitability performance, boasting an extraordinary return on equity metric of 61.8% over the past twelve months. this is indicative of the efficacy with which the company can convert shareholders' equity to profits.

trading volume

despite the strong profitability figures, barbara bui's trading volume is undergoing a steep decline. monday's final reported volume registered at a mere 1, a staggering 96% decrease from its average trading volume of 33 shares per day.

growth prospects

at its fundamental level, the company has been indicating positive growth signs. its year-on-year quarterly revenue expansion has increased by 7.9% to reach 10.92m for the last twelve months.

however, despite historically strong profitability and growth metrics, the recent tumbling of barbara bui's stock price and trading volume is causing concern among shareholders and other company stakeholders. such marked fluctuations could signal hidden market currents potentially threatening its future performance.

more news about barbara bui (bui.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com